EFTA02715650Set 11
2015-06-253p2,323w
drug poses apeutic efficacy and risk. Patients 20150519/103516/BILLS-1146ih.pdf).
2. Kesselheim AS, Tan YT. Avom J. The roles
"minimal risk." and physicians would not benefit of academia, rare diseases. and repurposing ... call for increased NIH are available with the full text of this ankle 4. Avom J. Approval of a tuberculosis drug
funding may prove to be its most at NEJM.org
https://www.justice.gov/epstein/files/DataSet%2011/EFTA02715650.pdf